Stock search

Ticker or company name

Merck & Co.

MRK · NYSE · Pharmaceuticals

$144,46Down −3,30 (−2,23%)today

Quotes delayed up to 15 min. Updated 16 Nov, 16:00 New York time

Market cap
$364 bn
Div. yield
2,9%
Year to date
+40,4%
52 weeks: $90,90$156,92

Ratio score

38/100
Ratio would not consider buying

based on 8 metrics as of 16.11.2026 ·

Verdict by our methodology based on current metrics. Not an investment recommendation.

Key metrics

2 ✓ · 2 — · 4 ✕ · 2 n/a · hover over a row or tap it to see the trend

All metrics

MetricValue5-year medianIndustry median
P/E TTM148,520,041,8
Forward P/E18,7—12,4
PEG25,7—3,3
P/S5,44,53,4
EV/EBITDA46,116,124,0
P/FCF24,7—14,0
P/B8,15,98,1

Industry median — across 6 profitable companies in “Pharmaceuticals” in Ratio. Revenue and EPS forecasts for future years and the number of employees are in the paid data plan.

Price chart

Compare with

Choose a stock

Closing prices adjusted for splits and dividends. The S&P 500 index and the intraday chart come later.

Analysts

Ratings, 35 analysts

Buy
25
Hold
10
Sell
0

Beat the EPS forecast in 4 of the last 4 quarters

QuarterEstimateActualSurprise
Q3 20262,102,49Up +18,5%
Q2 2026−0,27−0,13Up +52,3%
Q1 2026−1,52−1,28Up +16,0%
Q4 20252,032,09Up +3,0%

Price targets and yearly revenue and EPS forecasts are in the paid data plan. These are analysts' opinions, not our verdict.

Financials in charts

MetricQ3'26Q2'26Q1'26Q4'25Q3'25Q2'25Q1'25Q4'24Q3'24Q2'24Q1'24Q4'23
Revenue18,1 bn16,6 bn16,3 bn16,4 bn17,3 bn15,8 bn15,5 bn15,6 bn16,7 bn16,1 bn15,8 bn14,6 bn
EPS2,04−0,54−1,721,202,321,762,011,481,242,141,87−0,48
Margin28,0%−8,0%−26,0%18,1%33,5%28,0%32,7%24,0%19,0%33,9%30,2%−8,4%
FCF5,52 bn4,48 bn2,93 bn1,82 bn6,84 bn2,53 bn1,17 bn2,51 bn8,51 bn4,85 bn2,23 bn−743 m

From SEC reports. TTM is the sum of 4 quarters; a year is TTM at the end of the calendar year. Forecast bars are in the paid data plan.

Owners

Ownership structure and major holders (13F filings) are in the paid data plan. They are not part of the score or the traffic light.

Insider trades over 12 months

Over 12 months: no purchases, sales $70,7 m.

NameAmountSharesPrice
guindo chirfi13 Aug 2026 · sale$1,35 m10 000$135,00
zachary jennifer12 Aug 2026 · sale$10,7 m80 315$133,46
deluca richard r.12 Aug 2026 · sale$79 222600$132,04
deluca richard r.12 Aug 2026 · sale$1,46 m11 099$131,61
deluca richard r.11 Aug 2026 · sale$718 2615 427$132,35
deluca richard r.11 Aug 2026 · sale$973 1657 410$131,33
deluca richard r.10 Aug 2026 · sale$2,71 m20 784$130,43
guindo chirfi6 Aug 2026 · sale$1,97 m15 000$131,00
deluca richard r.6 Aug 2026 · sale$39 307300$131,02
deluca richard r.6 Aug 2026 · sale$643 9934 945$130,23
deluca richard r.6 Aug 2026 · sale$105 472805$131,02
maraldo david r.5 Aug 2026 · sale$345 7362 686$128,72
maraldo david r.5 Aug 2026 · sale$1,25 m9 709$128,72
maraldo david r.5 Aug 2026 · sale$812 3396 311$128,72
williams david michael5 Aug 2026 · sale$4,47 m34 705$128,77

SEC Form 4. Titles and trading plans are not in the data. They are not part of the score or the traffic light.

About the company

Industry
Pharmaceuticals
Exchange
NYSE
Country
US
IPO date
1 Jan 1941

Company description, revenue by segment and region, and the CEO will come later.

Next report
date not announced

An AI summary of the earnings call will come later.

Peers

CompanyPrice
JNJJohnson & Johnson$282,5544would watch42,9+7,8%16,2%
PFEPfizer$28,8644would watch40,8+1,3%6,3%
BMYBristol Myers Squibb$62,9381would consider14,0+4,2%18,5%
LLYLilly (Eli)$1 431,6775would consider49,2+45,5%31,9%
ZTSZoetis$84,3975would consider12,4+1,2%26,1%
Compare with peers

Ratio — a score by our methodology, not an investment recommendation.